A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with Chemotherapy

Dowell, Jonathan E.; Johnson, David H.; Rogers, John; Shyr, Yu; McCullough, N.; Krozely, Peggy; DeVore, Ronald A.

doi:10.1023/a:1006433528750

Search citation statements

Order By: Relevance

Paper Sections

Select...

Hmaf Clinical Trials: Current Status and Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

2015

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 17 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite promising results in phase I clinical trials, there were disappointing patient responses to HMAF in phase II trials. Thirteen patients with advanced renal cell carcinoma, 16 patients with stage IV melanoma, patients with advanced nonsmall cell lung cancer previously treated with chemotherapy (carboplatin and paclitaxel ± radiation, cisplatin and CPT-11), and patients with nonsmall lung carcinoma were treated with 11 mg/m 2 HMAF by 5 min intravenous infusion on 5 consecutive days every 28 days. No significant response to the treatment was detected.…”

Section: Hmaf Clinical Trials: Current Status and Resultsmentioning

confidence: 99%